Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Interleukin-2 in HER2+ Metastatic Breast Cancer
NCT00006228Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2000
- Primary completion
- Jul 2003
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in breast cancer, sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate at 12 months and Toxicity at 12 months. Started Jul 2000; status: completed.
02
Drugs
aldesleukin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00006228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006228.